Selected Food and Drug Administration review issues for regulation of allogeneic islets of Langerhans as somatic cell therapy

Transplantation

Volumn 74, Issue 12, 2002, Pages 1816-1820

  Weber, Darin J ^a,b   McFarland, Richard D ^a   Irony, Ilan ^b  

^a TissueGene Inc   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOGRAFT; ARTICLE; CELL TRANSPLANTATION; CLINICAL PROTOCOL; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; INDUSTRY; INSULIN DEPENDENT DIABETES MELLITUS; MARKETING; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; SOMATIC CELL;

EID: 0037184808     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200212270-00034     Document Type: Article

References (39)

1. Shapiro AMJ, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230-238.
2. US Food and Drug Administration. Transcripts of the Meeting of the Biological Response Modifiers Advisory Committee: Discussion of Allogeneic Islet Transplantation. Manufacturing, preclinical and Clinical Issues, 20-21 March 2000. Available at: http://www.fda.gov/ohrms/dockets/ac/cber00.htm. Accessed October 4, 2002.
3. US Food and Drug Administration, Human Cells, Tissues, and Cellular and Tissue-Based Products: Establishment Registration and Listing. Final Rule, January 19, 2001. Federal Register. Available at: http://www.fda.gov/cber/rules/frtisreg011901.pdf. Accessed October 4, 2002.
4. US Food and Drug Administration. Application of Current Statutory Authorities to Human Somatic Cell Therapy Products and Gene Therapy Products: Notice. 1993 Federal Register 58FR, 53248.
5. Kessler DA, Siegel JP, Noguchi PD, et al. Regulation of somatic cell therapy and gene therapy by the Food and Drug Administration. N Engl J Med 1993; 329: 1169-1173.
6. Public Health Service Act, Title 42, USC §262, §351.
7. Federal Food, Drug and Cosmetic Act, Title 21, USC §321(g), §201(g).
8. US Food and Drug Administration. Letter from K Zoon, Center for Biologics Evaluation and Research, to Transplant Centers Concerning Allogeneic Pancreatic Islets for Transplantation. 8 September 2000. Available at: http://www.fda.gov/cber/ltr/allpan090800.htm. Accessed October 4, 2002.
9. Investigational New Drug Applications, Title 21, US Code of Federal Regulations, Part 312.
10. General Principles of an IND Submission, Title 21, US Code of Federal Regulations, Part 312, §22.
11. US Food and Drug Administration. Guidance for Industry: Guidance for Human Somatic Cell Therapy and Gene Therapy. March 1998. Available at: http://www.fda.gov/cber/gdlns/somgene.pdf. Accessed October 4, 2002.
12. US Food and Drug Administration. Guideline on Sterile Drugs Produced by Aseptic Processing. 1987.
13. Current Good Manufacturing Practices, Title 21, US Code of Federal Regulations, Parts 210, 211.
14. Lakey J, Warnock GL, Rajotte RV, et al. Variables in organ donors that affect the recovery of human islets of Langerhans. Transplantation 1996; 15: 1047-1053.
15. General Biological Products Standards, Title 21, US Code of Federal Regulations, Part 610.
16. Gaber A, Fraga DW, Callicott CS, et al. Improved in vivo pancreatic islet function after prolonged in vitro islet culture. Transplantation 2001; 72(11): 1730-1736.
17. Lakey J, Helms LM, Kim T, et al. Serine-protease inhibition during islet isolation increases islet yield from human pancreases with prolonged ischemia. Transplantation 2001; 72: 565-570.
18. Lakey J, Anderson T, Rajotte R. Novel approaches to cryopreservation of human pancreatic islets. Transplantation 2001; 72(6): 1005-1011.
19. Matsumoto S, Kandaswamy R, Sutherland DE, et al. Clinical application of the two-layer (University of Wisconsin solution/perfluorochemical plus O2) method of pancreas preservation before transplantation. Transplantation 2000; 70(5): 771-774.
20. Zeng Y, Ricordi C, Lendoire J, et al. The effect of prednisone on pancreatic islet autografts in dogs. Surgery 1993; 113: 98-102.
21. Knetemonm NM, Lakey JR, Wagner T, Finegood D. The metabolic impact of rapamycin (sirolimus) in chronic canine islet graft recipients. Transplantation 1996; 61: 1206-1210.
22. Yakimets WJ, Lakey JR, Yatscoff RW, et al. Prolongation of canine pancreatic islet allograft survival with combined rapamycin and cyclosporine therapy at low doses. Rapamycin efficacy is blood level related. Transplantation 1993; 56: 1293-1298.
23. Chen H, Qi S, Xu D, et al. Combined effect of rapamycin and FK506 in prolongation of small bowel graft survival in the mouse. Transplant Proc 1998; 30: 2579-2581.
24. Vu M, Qi S, Xu D, et al. Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat. Transplantation 1997; 64: 1853-1856.
25. Ricordi C, Gray DW, Hering BJ, et al. Islet isolation assessment in man and large animals. Acta Diabetol Lat 1990; 27: 185-195.
26. Kahan B. Cyclosporin A, FK506, rapamycin: The use of a quantitative analytic tool to discriminate immunosuppressive drug interactions. J Am Soc Nephrol 1992; 2: S222-S227.
27. Arita S, Nagai T, Ochiai M, et al. Prevention of primary nonfunction of canine islet autografts by treatment with pravastatin. Transplantation 2002; 73: 7-12.
28. Vasir B, Jonas JC, Steil GM, et al. Gene expression of VEGF and its receptors Flk-1/KDR and Flt-1 in cultured and transplanted rat islets. Transplantation 2001; 71: 924-935.
29. Brandhorst D, Brandhorst H, Zwolinski A, et al. High-dosed nicotinamide decreases early graft failure after pig to nude rat intraportal islet transplantation. Transplantation 2002; 73: 74-79.
30. Benhamou P. Immunomodulation with CTLA4-Ig in islet transplantation. Transplantation 2002; 73: S40-S42.
31. Wennberg L, Song Z, Bennet W, et al. Diabetic rats transplanted with adult porcine islets and immunosuppressed with cyclosporine A, mycophenolate mofetil, and leflunomide remain normoglycemic for up to 100 days. Transplantation 2001; 71: 1024-1033.
32. Lopez-Avalos M, Tatarkiewicz K, Sharma A, et al. Enhanced maturation of porcine neonatal pancreatic cell clusters with growth factors fails to improve transplantation outcome. Transplantation 2001; 71: 1154-1162.
33. Mathews C, Langley S, Leiter E. New mouse model to study islet transplantation in insulin-dependent diabetes mellitus. Transplantation 2002; 73: 1333-1359.
34. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite guidelines: General Considerations for Clinical Trials, 1997. Available at: http://www.ich.org/pdfICH/e8.pdf. Accessed October 4, 2002.
35. US Food and Drug Administration. Guidance for Industry: Providing Clinical Evidence of Effectiveness for Human Drugs and Biological Products. 1998. Available at: http://www.fda.gov/cber/gdlns/clineff.pdf. Accessed October 4, 2002.
36. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guidelines: Guideline for Good Clinical Practice. May 1996. Available at: http://www.ich.org/pdfICH/e6.pdf. Accessed October 4, 2002.
37. Title 21, US Code of Federal Regulations, Parts 50, 54, 56, and 312. Available at: http://www.fda.gov/cber/ind/ind.htm. Accessed October 4, 2002.
38. National Cancer Institute. Common Toxicity Criteria. Available at: http://ctep.cancer.gov/reporting/ctc.html. Accessed October 4, 2002.
39. IND Safety Reports and Annual Reports, Title 21, US Code of Federal Regulations, Parts 312.32 and 312.33.